XenoPort to Release Second Quarter Financial Results on August 3, 2011

SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its second quarter financial results on August 3, 2011 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.

To access the conference call via the Internet, go to www.XenoPort.com. Please join the call at least 15 minutes prior to the start to ensure time for any software downloads that may be required.

To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 86743845.

The replay of the conference call may be accessed that same day after 8:00 p.m. Eastern Time, via the Internet, at www.XenoPort.com, or via phone at 1-800-642-1687 for domestic callers, or 706-645-9291 for international callers. The reference number to enter the replay of the call is 86743845.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. In April 2011, the FDA approved XenoPort’s first product, known in the United States as Horizant™ (gabapentin enacarbil) Extended-Release Tablets. Our collaborator in the United States, GlaxoSmithKline, began promoting Horizant in July 2011. Gabapentin enacarbil is being developed in partnership with Astellas Pharma Inc. for the potential treatment of restless legs syndrome in Japan. XenoPort’s pipeline of product candidates includes potential treatments for patients with neuropathic pain, spasticity and Parkinson’s disease. To learn more about XenoPort, please visit the web site at www.XenoPort.com.

XenoPort is a registered trademark.

Horizant is a trademark of GlaxoSmithKline.

XNPT2F



CONTACT:

XenoPort, Inc.
Jackie Cossmon, 408-616-7295
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.